Results 181 to 190 of about 8,118 (202)
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8552-8559, September 2026.ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede +10 more
wiley +1 more source
Non‐Invasive Assessment of Endothelial Dysfunction and Arterial Stiffness in Fontan Circulation
European Journal of Clinical Investigation, Volume 56, Issue 9, September 2026.The Fontan procedure is the definitive treatment for complex congenital heart disease, creating a circulation without a subpulmonary ventricle. This altered hemodynamic state negatively affects endothelial function, contributing to progressive organ dysfunction and long‐term morbidity.
Amalia Baroutidou +5 more
wiley +1 more source
Effect of Perinatal and Maternal Factors on Blood Pressure and Adiposity at Age 3
The Journal of Clinical Hypertension, Volume 28, Issue 9, September 2026.ABSTRACT The specific aim of the project was to evaluate the relationship between perinatal and maternal factors on childhood blood pressure (BP) and adiposity outcomes at Age 3. A retrospective case‐control study of 128 children and their mothers enrolled in the Generations Project was completed to examine the association between different perinatal ...
Katie Margolis +4 more
wiley +1 more source
The RAAS Goodfellas in Cardiovascular System [PDF]
Journal of Clinical Medicine, 2023 In the last two decades, the study of the renin–angiotensin–aldosterone system (RAAS) has revealed a counterregulatory protective axis. This protective arm is characterized by ACE2/Ang 1-7/MasR and Ang 1-9 that largely counteracts the classic arm of the ...
Giovanni Bertoldi +2 more
exaly +2 more sources
Revisiting RAAS blockade in CKD with newer potassium-binding drugs
Kidney International, 2018 Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agents blocking the renin angiotensin aldosterone system (RAAS) as first-line antihypertensive therapy based on randomized trials ...
Panagiotis Georgianos, Rajiv Agarwal
exaly +2 more sources
The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation
Veterinary SciencesThe renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in regulating cardiovascular function, fluid balance, and blood pressure. Recent research has revealed the RAAS’s influence extends beyond cardiovascular physiology, encompassing key ...
Giacomo Rossi +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Effects of RAAS Inhibitors in Patients with Kidney Disease
Current Hypertension Reports, 2017Fuyou Liu, Youming Peng, Yexin Liu
exaly